IGC Pharma Nears Phase 2 Alzheimer’s Trial Completion With Q4 Results Ahead

Aug 17, 2026

IGC Pharma (NYSE American: IGC) has reported its second-quarter 2026 results alongside a major milestone for its Alzheimer’s clinical program. The company’s Phase 2 CALMA trial of IGC-81 has reached its original target of 146 randomized patients and is now just six additional randomizations away from expected enrollment closure. IGC-81 is being evaluated as a potential treatment for agitation associated with Alzheimer’s dementia, with top-line Phase 2 results expected in the fourth quarter of 2026.

IGC Pharma also announced that its CEO and Principal Financial Officer elected to convert approximately $1.15 million owed to them into company shares rather than receive cash repayment, a move intended to preserve cash and further align management with shareholders. The company continues to develop its AI-enabled platforms focused on Alzheimer’s disease and aging-related data as it prepares for the next stage of its clinical program.

#IGCPharma
#IGC
#Alzheimers
#IGC81
#CALMATrial
#ClinicalTrials
#Biotechnology
#AlzheimersResearch
#DrugDevelopment
#ArtificialIntelligence
#HealthcareInnovation
#NYSEAmerican
#AnnaBerry
#NewsOut
#InvestorNews